Standout Papers

Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer 2017 2026 2020 2023 1.4k
  1. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer (2017)
    Karim Fizazi, Luis Fein et al. New England Journal of Medicine
  2. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial (2019)
    Karim Fizazi, Luis Fein et al. The Lancet Oncology

Immediate Impact

13 by Nobel laureates 8 from Science/Nature 67 standout
Sub-graph 1 of 20

Citing Papers

Prostate Cancer
2025 Standout
Renal cell carcinoma
2024 Standout

Works of Andrew Protheroe being referenced

Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial
2019 Standout
Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial
2016
and 1 more

Author Peers

Author Last Decade Papers Cites
Andrew Protheroe 3171 1333 927 1763 1349 122 5.8k
Hao Wang 2405 1898 683 1259 992 124 4.6k
Venkatraman Seshan 2330 2662 619 2892 1618 122 7.7k
Ingela Turesson 5372 2507 929 1894 2005 118 9.2k
Kevin M. Slawin 6736 1822 1470 1959 1277 180 9.7k
John Staffurth 2721 1058 735 829 860 115 4.2k
Albert J.H. Suurmeijer 2640 2097 1901 1515 587 206 8.0k
Vivian Weinberg 3291 2153 2076 885 753 172 7.6k
Geert J.L.H. van Leenders 5827 1199 1548 1672 1120 184 8.2k
Michael K. Brawer 6821 1082 1322 1510 1080 168 8.8k
Christina Messiou 2378 2049 559 974 489 174 5.6k

All Works

Loading papers...

Rankless by CCL
2026